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Anesthetic Consideration of Niemann-Pick Disease Type C 
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Abstract 
Niemann-Pick disease type C (NPC) is a rare, autosomal recessive, 
neurometabolic disorder associated with the accumulation of unesterified 
cholesterol in lysosomes and late endosomes. Because of multiple organ 
involvement and wide range of clinical manifestations, these patients will 
demand multiple diagnostic and therapeutic procedures requiring anesthesia. 
Since pathogenesis of this disease is still unknown and further investigations 
on cellular and molecular basis of NPC is needed. In this report we present a 
known case of NPC1 requiring anesthesia for Percutaneous Endoscopic 
Gastrostomy and a brief review about molecular basis and recent advances in 
this field.  
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Albert Niemann and Ludwig Pick in 1920’s 
introduced an autosomal recessive disease 
characterized by disorders in liposomal lipid and 
sphyngomyeline storage, by common feature of 
hepatosplenomegaly with or without neurological 
involvements. Later in 1958 Crocker proposed a four 
group classification (A-D) based on age of onset, 
clinical implications and level of sphingomyelin 
storage in tissues (1, 2). 
Type A defined by early CNS involvements 
and massive storage of visceral and cerebral 
sphingomyelin. Type B has a chronic course with 
visceral involvement and sparing CNS. Type C and D 
defined by sub-acute CNS involvement with milder 
visceral storage. Type D patients were individualized 
essentially on their homogenous Nova Scotia Acadian 
origin (1, 3). 
Niemann-Pick Type C (NP-C), with a 
prevalence of 1/100000 – 1/120000, is characterized 
by progressive, disabling neurologic features 
(cerebellar ataxia, dysarthria, dysphagia, progressive 
dementia, cataplexy, seizures, dystonia and 
supranuclear gaze palsy) with mild visceral storages 
(liver, spleen, lungs) (1, 3). It is caused by mutations 
in either of two genes mentioned as NPC1 and NPC2. 
NPC1 is involved in 95% of patients, including 
type D while NPC2 is present in certain families. 
These genes participate in cellular post lysosomal/late 
endosomal transport of cholesterol (4, 5). These 
changes result in sequestration of unesterified 
cholesterol in lysosomes and late endosomes (1, 2). 
Onset of NPC ranges from perinatal period till 
seventh decade of life, therefore life expectancy range 
from few days (Fetal hydrops) till over 60s; though 
majority of them die between 10 and 25 years from 
neurologic manifestations (1, 2). 
Diagnosis of this disease is based on 
multidisciplinary process involving clinical 
assessments, histological, electron microscopic tests, 
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biochemical, and molecular genetics laboratory 
studies (2). Final confirmation is based on 
demonstration of characteristics intralyposomal 
accumulation of unesterified cholesterol (Filipin 
staining in skin fibroblasts) and/or the identification 
of mutations in either the NPC1 or NPC2 genes (2). 
Novice areas of diagnosis are plasma oxysterols 
(particularly cholestane-3β,5α,6β-triol and 7-
ketocholesterol), certain sphingolipids such as 
lysosphingosine (2). 
Major clinical manifestations are dysphagia, 
recurrent aspirations leading to gastrostomy, severe 
epilepsy, severe hepatosplenomegaly and dramatic 
psychiatric disorders (1, 3, 6). 
The only available approved therapy is 
Miglustat which could be prescribed as neurologic 
symptoms appeared. This drug can slower the 
progression of neurologic damage and also have some 
positive impacts on developing and progression of 
dysphagia (4, 6 7). 
As discussed, the nature of the disease made it 
a target for diagnostic and therapeutic procedures that 
require anesthesia. This report will address anesthesia 
management of Niemann-Pick C and discuss cellular 
and molecular advances in this field. 
Brief Report 
A 9 years old boy, known case of Niemann-
Pick C (NPC), was admitted to our hospital due to 
uncontrolled seizures and respiratory distress. 
He was born at full term to nonconsanguineous 
parents by normal vaginal delivery without 
remarkable family history. His growth was normal in 
his first 6 months. Later on, splenomegaly observed 
and neurodevelopmental milestones were lost. Further 
examinations confirmed the diagnosis of NPC by 
cutaneous biopsy and Filipin staining. Since then 
Meglustat 100 mg TDS was initiated. He had 
developmental progression for the next 6 years till 
neurologic symptoms including seizures, ataxia, 
incontinency, and dysphagia emerged. His weekly 
seizures were managed by Lamotrigine, Sodium 
valproate and Prednisolone. Unfortunately respiratory 
symptoms (Productive cough, Wheezing) occurs from 
former month due to uncontrolled seizures, dysphagia 
 
Fig. 1.  (A) Normal esterification of cholesterol; (B) Esterification of cholesterol in NPC1/2. 
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and severe sialorrhea, suggesting aspirating 
pneumonia. 
During his admission, antibiotics were 
prescribed. Antiepileptics changed to Topiramate and 
Levetiracetam. He was feeding through NG tube. 
After alleviation of respiratory symptoms and control 
of seizures, he was transferred for Percutaneous 
Endoscopic Gastrostomy. 
On preoperative assessment, the patient 
weighed 40 Kg, the physical examination revealed 
bilateral rhonchi with increase in respiratory work. 
Baseline SpO2 was 94% in room air. Laboratory Data 
was within normal range. 
Atropine 0.8mg/IV, Midazolam 1mg/IV and 
Fentanyl 50μg/IV was prescribed as premedication in 
endoscopic ward under full monitoring (ECG, Pulse 
oximetry, and NIBP). Induction was achieved by 
Propofol 80 mg/IV and the patient was intubated with 
ETT #5.0 under Direct Laryngoscopy. Infusion of 
Propofol was started for maintenance at 250 mg/hr. 
During procedure vital sign was stable and about 20 
minutes after secession of maintenance the patient 
was extubated and transferred to ward. 
 
Table 1: Anesthetic consideration of Niemann-Pick Disease; TV, tidal volume, RR, respiratory rate, FRC, 
functional residual capacity, TIVA, total intravenous anesthesia. 
Organ System Associated Comorbidities Anesthetic Consideration 
Respiratory System Restrictive Lung Disease Lower TV and higher RR 
 Recurrent Aspiration Pneumonia 
Gastrointestinal System Hepatosplenomegaly Decreased FRC and Increase in 
episodes of desaturation 
 Ascites 
 Liver Failure Consider Dosage Adjustments 
 Sialorrhea Anticholinergic as 
premedication could be 
beneficial 
Airway Difficult intubation Consider anticipated difficult 
intubation algorithm 
Hematologic System Thrombocytopenia Increased risk of bleeding 
Central Nervous System  Seizure  Continue antiepileptic agents 
and avoid epileptogenic drugs 
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Discussion 
NPC is caused by mutations in one of the two 
genes called NPC1 or NPC2. 95% of cases have 
NPC1 mutation which encodes a large glycoprotein in 
late endosomal location. This gene mapped to 
chromosome 18q11-q12, spans 56 kbp and contains 
25 exons. NPC2 encodes a small soluble lysosomal 
protein which binds cholesterol with high affinity (8). 
NPC2 mapped to chromosome 14q24.3, spans 13.5 
Kbp and contains 5 exons. Deficiency in both types 
causes impairment in processing and utilization of 
endocytosed cholesterol (1, 8). The cellular hall mark 
of this disease is inability of cholesterol to transport 
from late endosomes to plasma membrane or 
reticulum endoplasmic therefore accumulation of 
cholesterol and products will occur (Figure 1) (1). 
Therefore cholesterol storage is impeded and 
resulted in different pattern of accumulation in 
neuronal and extra-neuronal tissues. These changes 
cause sphingomyelin metabolism alteration in extra 
neuronal tissues. Unesterified cholesterol, 
sphingomyelin, bisphosphate, glycolipids, and free 
sphingosine and sphinganine will accumulate in liver 
and spleen(1). In neurons, accumulation of 
Glycosphingolipids including GM2 and GM3 
gangliosides occurs and cause meganeurite formation, 
growth of ectopic dendrites, neurofibrillary tangles 
formation, neuroinflammation, and neuroaxonal 
dystrophy (8). On the other hand, some proteins like 
Rab9 or mannose-6-phosphate receptors transfer to 
cell membrane by late lysosomal system. Cholesterol 
accumulation could also impair this trafficking (1). 
Unexplainably neural death occurs mostly in Purkinje 
cells of the cerebellum. The function of these proteins 
are not defined yet so the exact mechanism and 
pathophysiology remains a mystery (1). 
The only approved therapy for NPC so far is 
Miglustat (N-butyl-deoxynojirimycin). It is an 
iminosuger inhibitor of glucosylceramide synthase 
(1). This drug can stabilize the neurological 
manifestations including dysphagia (6). Miglustat by 
inhibiting glucosylceramide synthase reduce the 
synthesis of glucosylceramide-based 
glycosphingolipid in CNS (6). But long term clinical 
outcomes are still unclear (6). Other drugs used for 
symptom therapy including antiepileptic drugs 
(treatment of seizure), clomipramine, protriptyline, or 
modafinil (treatment of Cataplexy), anticholinergic 
agents (treatment of dystonia and tremor), Melotonin 
(treatment of insomnia). Physiotherapy for 
management of muscle spasticity and contracture is 
useful. As the major cause of mortality in these 
patients is aspiration pneumonia, the most important 
part of managing this disease is handling feeding 
abnormalities (1, 6). Current researches in the field of 
treating this disease is based on animal models mostly 
transgenic mice and cats and also testing various 
compounds like imatinib, curcumin, NSAIDs, 
neurosteroids (allopregnolone) and 2-HP-ß-
cyclodextrin. The last compound showed significant 
improvement in disease natural history in animal 
models but needs further investigations (1). 
The exact function of NPC genes are unknown 
therefore the pathophysiology of this disease is still a 
mystery (4). So the target metabolite in brain causing 
the neuroinflammatory responses remains unknown. 
These results are in lack of a biochemical blood test 
for evaluating prognosis or diagnosis (1, 4). Currently 
the gold standard for diagnosis is skin biopsy however 
recent advances suggest oxysterol profile as a 
biomarker for NPC. Although more researches are 
needed to define it as an indicator, these findings 
could change the future treatment and research 
developments (1, 4). 
As mentioned above, NPC is a disease which 
involves multiple organs including central nervous 
system, respiratory system and gastrointestinal system 
(hepatosplenomegaly). Therefore this disease could 
interfere with routine anesthetic plans (3, 5). 
Restrictive lung disease arise from recurrent 
aspirations demand specific consideration in 
ventilator setup, so lower tidal volumes and increase 
in respiratory rate could be helpful for these patients. 
Another problem is the liver damage caused by 
storage of lipids, which needs careful selection of 
anesthetic drugs (5). Also hepatomegaly could 
accompany ascites which leads to decreased 
Functional Residual Capacity (3). there are some 
reports indicating the association between NPC and 
difficult airway therefore considering options for 
intubation would be wise (1). on the other hand, 
thrombocytopenia accompanied by this disease, could 
potentiate the risk of bleeding (1). Due to vigorous 
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secretions anticholinergic drugs prior to anesthesia 
could improve the outcome of the procedure (3). It is 
demonstrated that hyperventilation plus high 
concentrations of Sevoflurane could induce seizures. 
Therefore to avoid this phenomenon continuing 
antiepileptic agents in perioperative period and use of 
TIVA instead of volatiles is recommended (3). The 
technique of choice is the one in which satisfactory 
condition for procedure is established rapidly and 
safely and also the recovery should be safe and 
predicted with minimal sequel for the patient (5). 
Conclusion 
Although almost a century has passed since the 
introduction of NPC, there are many unknown aspects 
which could be a good target for future researches. 
These unrevealed areas of investigations include 
absence of biomarker for evaluating treatments, exact 
pathophysiology, and introduction of effective 
treatment. Diversity of clinical manifestations 
together with unknown pathophysiology results in the 
complexity and enigmatic features of this disease. 
Some of manifestations of NPC can affect the 
anesthetic plan. These comorbidities are summarized 
in table 1. In conclusion by considering comorbidities 
and anesthetic implications mentioned above and 
severity and type of procedure or surgery, each 
patient with different clinical symptoms could benefit 
from different anesthetic approaches (1, 5). 
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